Detalhe da pesquisa
1.
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Mol Cancer Ther
; 21(7): 1047-1059, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511740
2.
Setting the chaperonin timer: the effects of K+ and substrate protein on ATP hydrolysis.
Proc Natl Acad Sci U S A
; 105(45): 17334-8, 2008 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18988745
3.
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.
Mol Immunol
; 44(11): 3049-60, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17241664
4.
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
Clin Cancer Res
; 23(6): 1506-1518, 2017 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663593
5.
Antibody humanization by framework shuffling.
Methods
; 36(1): 43-60, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15848074